Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2020 3
2021 2
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study.
Verbeek MWC, Rodríguez BS, Sedek L, Laqua A, Buracchi C, Buysse M, Reiterová M, Oliveira E, Morf D, Oude Alink SR, Barrena S, Kohlscheen S, Nierkens S, Hofmans M, Fernandez P, de Costa ES, Mejstrikova E, Szczepanski T, Slota L, Brüggemann M, Gaipa G, Grigore G, van Dongen JJM, Orfao A, van der Velden VHJ. Verbeek MWC, et al. Among authors: laqua a. Cytometry B Clin Cytom. 2023 Sep 22. doi: 10.1002/cyto.b.22143. Online ahead of print. Cytometry B Clin Cytom. 2023. PMID: 37740440
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis.
Schilhabel A, Walter PJ, Cramer P, von Tresckow J, Kohlscheen S, Szczepanowski M, Laqua A, Fischer K, Eichhorst B, Böttcher S, Schneider C, Tausch E, Brüggemann M, Kneba M, Hallek M, Ritgen M. Schilhabel A, et al. Among authors: laqua a. Cancers (Basel). 2022 Oct 7;14(19):4917. doi: 10.3390/cancers14194917. Cancers (Basel). 2022. PMID: 36230840 Free PMC article.
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Verbeek MWC, Buracchi C, Laqua A, Nierkens S, Sedek L, Flores-Montero J, Hofmans M, Sobral de Costa E, Nováková M, Mejstrikova E, Barrena S, Kohlscheen S, Szczepanowski M, Kulis J, Oliveira E, Jugooa R, de Jong AX, Szczepanski T, Philippé J, van Dongen JJM, Orfao A, Brüggemann M, Gaipa G, van der Velden VHJ. Verbeek MWC, et al. Among authors: laqua a. Br J Haematol. 2022 Apr;197(1):76-81. doi: 10.1111/bjh.17992. Epub 2021 Dec 8. Br J Haematol. 2022. PMID: 34881427 Free PMC article.
Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G, Laqua A, Lettau M, Baldus CD, Brüggemann M. Chitadze G, et al. Among authors: laqua a. Expert Rev Hematol. 2020 Nov;13(11):1211-1233. doi: 10.1080/17474086.2020.1831380. Epub 2020 Nov 4. Expert Rev Hematol. 2020. PMID: 33000968
Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study.
Lhermitte L, Barreau S, Morf D, Fernandez P, Grigore G, Barrena S, de Bie M, Flores-Montero J, Brüggemann M, Mejstrikova E, Nierkens S, Burgos L, Caetano J, Gaipa G, Buracchi C, da Costa ES, Sedek L, Szczepański T, Aanei CM, van der Sluijs-Gelling A, Delgado AH, Fluxa R, Lecrevisse Q, Pedreira CE, van Dongen JJM, Orfao A, van der Velden VHJ; EuroFlow Consortium. Lhermitte L, et al. Mod Pathol. 2021 Jan;34(1):59-69. doi: 10.1038/s41379-020-00677-7. Epub 2020 Sep 30. Mod Pathol. 2021. PMID: 32999413 Free PMC article.
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.
Lenk L, Winterberg D, Vogiatzi F, Laqua A, Spory L, Mayar A, Dietterle A, Münch G, Vokuhl C, Richter J, Polson AG, Schüler T, Kahlert UD, Peipp M, Valerius T, Schrappe M, Cario G, Jumaa H, Hobeika E, Brüggemann M, Alsadeq A, Schewe DM. Lenk L, et al. Among authors: laqua a. Hemasphere. 2022 Jul 15;6(8):e754. doi: 10.1097/HS9.0000000000000754. eCollection 2022 Aug. Hemasphere. 2022. PMID: 35935606 Free PMC article. No abstract available.
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM. Lenk L, et al. Among authors: laqua a. Blood. 2024 Mar 22:blood.2023021088. doi: 10.1182/blood.2023021088. Online ahead of print. Blood. 2024. PMID: 38518105